Focus Partners Wealth Purchases 159,419 Shares of Johnson & Johnson $JNJ

Key Points

• Focus Partners Wealth increased its stake in Johnson & Johnson by 15.4%, acquiring an additional 159,419 shares, bringing its total holdings to 1,193,378 shares worth approximately $197.9 million.
• Insider selling took place as EVP Jennifer L. Taubert sold 56,471 shares for over $10 million, resulting in a 24.08% decrease in her ownership of the stock.
• Johnson & Johnson reported $2.77 EPS for its last quarter, exceeding expectations, with a revenue of $23.74 billion, which is a 5.8% increase year-over-year.

Focus Partners Wealth boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 15.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,193,378 shares of the company's stock after acquiring an additional 159,419 shares during the period. Focus Partners Wealth's holdings in Johnson & Johnson were worth $197,910,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Elios Financial Group Inc. raised its stake in Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after acquiring an additional 66 shares in the last quarter. Atlantic Family Wealth LLC raised its stake in Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after acquiring an additional 67 shares in the last quarter. MBA Advisors LLC raised its stake in Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after acquiring an additional 68 shares in the last quarter. Sovereign Financial Group Inc. raised its stake in Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after acquiring an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc lifted its stake in Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after buying an additional 69 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research reports. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. UBS Group boosted their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Finally, Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Friday, September 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $177.12 on Wednesday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The business has a 50 day simple moving average of $169.51 and a 200-day simple moving average of $161.02. The stock has a market capitalization of $426.57 billion, a PE ratio of 18.94, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the prior year, the business earned $2.82 earnings per share. The company's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.